BR112023003652A2 - Composição peptídica para prevenção ou tratamento da doença de alzheimer - Google Patents
Composição peptídica para prevenção ou tratamento da doença de alzheimerInfo
- Publication number
- BR112023003652A2 BR112023003652A2 BR112023003652A BR112023003652A BR112023003652A2 BR 112023003652 A2 BR112023003652 A2 BR 112023003652A2 BR 112023003652 A BR112023003652 A BR 112023003652A BR 112023003652 A BR112023003652 A BR 112023003652A BR 112023003652 A2 BR112023003652 A2 BR 112023003652A2
- Authority
- BR
- Brazil
- Prior art keywords
- suppression
- alzheimer
- peptide composition
- disease
- prevention
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 208000024827 Alzheimer disease Diseases 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000001629 suppression Effects 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000016396 cytokine production Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 230000003959 neuroinflammation Effects 0.000 abstract 1
- 239000012466 permeate Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000004845 protein aggregation Effects 0.000 abstract 1
- 102000013498 tau Proteins Human genes 0.000 abstract 1
- 108010026424 tau Proteins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200108861A KR20220027685A (ko) | 2020-08-27 | 2020-08-27 | 알츠하이머 치매 예방 또는 치료용 펩타이드 조성물 |
| PCT/KR2021/011386 WO2022045775A1 (ko) | 2020-08-27 | 2021-08-25 | 알츠하이머 치매 예방 또는 치료용 펩타이드 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023003652A2 true BR112023003652A2 (pt) | 2023-03-28 |
Family
ID=80353646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023003652A BR112023003652A2 (pt) | 2020-08-27 | 2021-08-25 | Composição peptídica para prevenção ou tratamento da doença de alzheimer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240082345A1 (zh) |
| EP (1) | EP4212167A1 (zh) |
| JP (1) | JP2023539752A (zh) |
| KR (1) | KR20220027685A (zh) |
| CN (1) | CN116249542A (zh) |
| AU (1) | AU2021331859A1 (zh) |
| BR (1) | BR112023003652A2 (zh) |
| CA (1) | CA3190919C (zh) |
| WO (1) | WO2022045775A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3168643A1 (en) * | 2019-02-28 | 2020-09-03 | Dandi Bioscience Inc. | Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising same, and antibacterial composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT501621A1 (de) * | 2005-03-15 | 2006-10-15 | Mattner Frank Dr | Zusammensetzungen zur verwendung bei der vorbeugung und behandlung der alzheimer- erkrankung |
| KR101785050B1 (ko) * | 2014-12-10 | 2017-10-13 | 건국대학교 글로컬산학협력단 | Ａｄｋ 단백질 및 항생제를 유효성분으로 포함하는 패혈증 또는 패혈증성 쇼크의 예방 또는 치료용 조성물 |
| KR101755097B1 (ko) | 2015-05-22 | 2017-07-07 | 단국대학교 천안캠퍼스 산학협력단 | 알츠하이머성 치매 치료를 위한 뇌 조직 재생용 약제학적 조성물 |
| EP3440096A4 (en) * | 2016-04-06 | 2019-11-13 | Ewha University-Industry Collaboration Foundation | PEPTIDE WITH ABILITY TO CELL MEMBRANE PENETRATION |
| JP7184054B2 (ja) | 2018-01-11 | 2022-12-06 | 東洋紡株式会社 | 測定試料希釈液およびキットおよび測定方法 |
| JP2021525785A (ja) * | 2018-06-08 | 2021-09-27 | ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ オクラホマ | アルツハイマー病および関連状態を処置するためのペプチド治療薬 |
| KR20210121132A (ko) * | 2019-01-28 | 2021-10-07 | 코바, 인크. | 치료용 펩티드 |
-
2020
- 2020-08-27 KR KR1020200108861A patent/KR20220027685A/ko not_active Application Discontinuation
-
2021
- 2021-08-25 WO PCT/KR2021/011386 patent/WO2022045775A1/ko active Application Filing
- 2021-08-25 US US18/042,815 patent/US20240082345A1/en active Pending
- 2021-08-25 CA CA3190919A patent/CA3190919C/en active Active
- 2021-08-25 BR BR112023003652A patent/BR112023003652A2/pt unknown
- 2021-08-25 CN CN202180053208.8A patent/CN116249542A/zh active Pending
- 2021-08-25 AU AU2021331859A patent/AU2021331859A1/en active Pending
- 2021-08-25 JP JP2023513622A patent/JP2023539752A/ja active Pending
- 2021-08-25 EP EP21862072.2A patent/EP4212167A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023539752A (ja) | 2023-09-19 |
| AU2021331859A1 (en) | 2023-03-16 |
| KR20220027685A (ko) | 2022-03-08 |
| CN116249542A (zh) | 2023-06-09 |
| CA3190919A1 (en) | 2022-03-03 |
| US20240082345A1 (en) | 2024-03-14 |
| WO2022045775A1 (ko) | 2022-03-03 |
| EP4212167A1 (en) | 2023-07-19 |
| CA3190919C (en) | 2023-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023003652A2 (pt) | Composição peptídica para prevenção ou tratamento da doença de alzheimer | |
| BR0210721A (pt) | Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição | |
| PT721449E (pt) | Inibidores da producao da proteina beta-amiloide | |
| AU2010251788B2 (en) | Novel agents for ameliorating motor disorder | |
| BR0214295A (pt) | Composto, método para tratar um paciente que tem ou prevenir um paciente de adquirir uma doença ou condição, e, método para produzir um composto | |
| BR112022017189A2 (pt) | Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1 | |
| BR112022019211A2 (pt) | Azaspirociclos como moduladores de lipase de monoacilglicerol | |
| Rak et al. | Neurotrophic effects of taurine on spiral ganglion neurons in vitro | |
| CO2020002992A2 (es) | Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides | |
| CO2023009089A2 (es) | Anticuerpos anti-n3pglu beta amiloide y usos de estos | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| Kalinowsky | Organic psychotic syndromes occurring during electric convulsive therapy | |
| Wiglusz et al. | Overlapping phenomena of bipolar disorder and epilepsy-a common pharmacological pathway | |
| Inagaki et al. | Effects of heat treatment on conformation and cell growth activity of alpha-lactalbumin and beta-lactoglobulin from market milk | |
| DE69126563T2 (de) | Verwendung einer Mischung von Peptiden and Aminosäuren für die Prophylaxis oder Behandlung von Dementia | |
| US10213480B2 (en) | Method of inhibiting microglial cell migration and treating traumatic brain injury | |
| Abkur | Isolated peripheral facial nerve palsy in multiple sclerosis | |
| Fu et al. | Effect of aging on visual attention: Evidence from the Attention Network Test | |
| Alsawafi et al. | Demyelinating polyneuropathy following scorpion sting envenomation; a case report and review of literature | |
| BR112022012676A2 (pt) | Composto químico e composição | |
| Istifo et al. | Long term effect of fluoxetine and memantine on biochemical markers of Alzheimer’s disease in scopolamine-induced mice | |
| Alkadhi | A rat model of pre-clinical Alzheimer’s disease | |
| BR112022003484A2 (pt) | Composição e método para inibir a acumulação, agregação e a formação de proteínas tau | |
| BR112023018354A2 (pt) | Métodos e usos de composições, componentes ou metabólitos de microbioma para tratar distúrbios oculares | |
| WO2023122280A3 (en) | Compositions and methods for treating skin defects |